Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis
Diabetes/Metabolism Research and Reviews · 2026-11 · 42 (8)
DOI: 10.1002/dmrr.70252 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 16.11.2026. Verfasst von Jie Yu und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The aim of this systematic review and network meta‐analysis was to compare the efficacy and safety of triple oral antidiabetic therapy (3OADs) and insulin‐based therapy in patients with type 2 diabetes after dual therapy failure. Materials and Methods Medline (PubMed), Embase, Web of Science, and Cochrane Library were systematically searched (from inception to September 1, 2023). The network meta‐analysis included randomized clinical trials (RCTs) of 3OADs and/or insulin‐based therapies after dual therapy failure. Mean difference (MD) was extracted for changes in HbA1c and body weight; odds ratio (OR) was extracted for hypoglycemia and adverse events.
Results
Forty‐two articles (13,911 adult patients) were analysed. 3OADs versus insulin‐based therapy showed comparable HbA1c reduction (MD 0.01%; 95% CI, −0.56 to 0.58), weight change (MD ‐1.59 kg; 95% CI, −3.67 to 0.48), hypoglycemia (OR 0.70; 95% CI, 0.37–1.30), and adverse events (OR 1.68; 95% CI, 1.00–2.82) at 22–36 weeks. Sensitivity analysis revealed that 3OADs significantly reduced weight compared with insulin‐based therapy (MD −3.30 kg; 95% CI, −5.56 to −1.05). No significant differences in HbA1c reduction, hypoglycemia incidence, or adverse events were observed between metformin (Met) + dipeptidyl peptidase‐4 inhibitor (DPP‐4i) + sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) and other 3OAD regimens. Meanwhile, Met + DPP‐4i + SGLT‐2i had the highest probability of achieving the greatest weight reduction.
Conclusions
Compared with insulin‐based therapy, 3OADs demonstrated comparable glucose‐lowering effects and safety profiles, with a significant weight‐sparing benefit observed in sensitivity analysis. Among all 3OAD combinations, Met + DPP‐4i + SGLT‐2i ranked first for weight loss, without increasing hypoglycemia risk.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, J., Rao, C., Cui, L., & Xiao, X. (2026). Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews, 42(8). https://doi.org/10.1002/dmrr.70252
Vancouver
Yu J, Rao C, Cui L, Xiao X. Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews. 2026;42(8). doi:10.1002/dmrr.70252
BibTeX
@article{Yu2026,
author = {Yu, Jie and Rao, Chong and Cui, Limei and Xiao, Xinhua},
title = {Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {8},
doi = {10.1002/dmrr.70252}
}
EUVIMED